These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27347439)

  • 1. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations.
    Fox RJ; Chan A; Gold R; Phillips JT; Selmaj K; Chang I; Novas M; Rana J; Marantz JL
    Neurol Clin Pract; 2016 Jun; 6(3):220-229. PubMed ID: 27347439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
    Chan A; Rose J; Alvarez E; Bar-Or A; Butzkueven H; Fox RJ; Gold R; Gudesblatt M; Haartsen J; Spelman T; Wright K; Ferraro D; Sola P; Hodgkinson S; Kalincik T; Lechner-Scott J; McGuigan C; Spach K; Chen C; Fam S; Wu F; Miller C
    Neurol Clin Pract; 2020 Dec; 10(6):510-519. PubMed ID: 33510947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
    Singer BA; Wray S; Gudesblatt M; Bumstead B; Ziemssen T; Bonnell A; Scaramozza M; Levin S; Shanmugasundaram M; Chen H; Mendoza JP; Lewin JB; Shankar SL
    Neurol Ther; 2024 Aug; 13(4):1273-1285. PubMed ID: 38935202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP; Wu L; Balshi A; Jun C; Baber U; Sloane JA
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
    J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Chen C; Parks B; Miller C
    Ther Adv Neurol Disord; 2020; 13():1756286420915005. PubMed ID: 32426039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Neurol Ther; 2017 Dec; 6(2):189-196. PubMed ID: 28780745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
    Chu L; Balusha A; Casserly C; Berger W; Morrow SA
    Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate.
    Sangurdekar D; Sun C; McLaughlin H; Ayling-Rouse K; Allaire NE; Penny MA; Bronson PG
    Front Genet; 2019; 10():1039. PubMed ID: 31749835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
    Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Longbrake EE; Mao-Draayer Y; Cascione M; Zielinski T; Bame E; Brassat D; Chen C; Kapadia S; Mendoza JP; Miller C; Parks B; Xing D; Robertson D
    Mult Scler; 2021 May; 27(6):883-894. PubMed ID: 32716690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.